» The Role of PARP Inhibition in Clinical Practice

Accredited e-learning: The Role of PARP inhibition in Clinical Practice

DNA Damage Response (DDR) and PARP inhibitors are promising but complex therapeutic strategies.

Understand why, where and how PARP inhibitors work in clinical practice, and look into the future of targeting DDR with this interactive free to access e-learning course. Designed to support you in selecting the appropriate treatment strategy with PARP inhibitors in the appropriate patient population and to provide the best possible patient care.

This course is endorsed by the Innovative Breast Cancer Research Group (SOLTI), the Gynecological Cancer Group Singapore (GCGS) and the Gynecologic Oncology Trial and Investigation Consortium (GOTIC).

Downloadable slides accompany this e-learning for your own use.

Prof. Jonathan A. Ledermann has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Clovis, Cristal Therapeutics, Pfizer, Roche and Seattle Genetics.

Dr Rebecca Dent has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Eisai, Genentech, Lilly, Merck, Novartis, Pfizer and Roche.

Dr Robert L. Coleman has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Aravive, ArQuel, Cell Medica, Clovis, Geistlich Pharma, Genetech, GenMab, ImmunoGen, Janssen, Medscape, Merck, Mersana, MoreHealth, OncLive, OncoMed, Physicians Educational Resource, Takeda, Tesaro, TRM Oncology and United Therapeutics.

Prof. Eric Pujade-Lauraine has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Clovis, Pfizer, Roche and Tesaro.

Other programmes of interest